A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)

Summary

This study was conducted: 1) to assess the clinical effect of Navarixin on the Psoriasis Activity and Severity Index (PASI), 2) to determine the effects of Navarixin on the Physician's Global Assessment (PGA), 3) to evaluate the safety and tolerability of Navarixin, and 4) to determine the multiple-dose pharmacokinetics of Navarixin.

Timeline

Start

2007-06-01

Primary completion

2007-10-01

Completion

2007-10-01

Drugs

Indications